🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ulm
Clinical trial register · Germany

Clinical Trials in Ulm, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Hamburg 25 Berlin 24 Munich 22 Ulm 21 Freiburg im Breisgau 20
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Ulm24 Hoffmann-La Roche23 AbbVie21 Novartis Pharmaceuticals14 Eli Lilly and Company13 Clear sponsor filter
Site location
Hamburg25 Berlin24 Munich22 Ulm21 Freiburg im Breisgau20
All 122 locations
Target enrolment
to

Trials with a site in Ulm

21 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide
AbbVie
Phase 3
520
Freiburg im Breisgau, Karlsruhe, Tübingen, Ulm, Würzburg, Hanover, Bonn, Cologne
2026-11-30
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065Neovascular Age-related Macular Degeneration
DrugSurabgene Lomparvovec
AbbVie
Phase 3
561
Freiburg im Breisgau, Tübingen, Ulm, Munich, Göttingen, Hanover, Bonn, Ludwigshafen am Rhein
2025-11-05
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
DrugsRisankizumab·Vedolizumab
AbbVie
Phase 3
573
Freiburg im Breisgau, Ulm, Dachau, Erlangen, Regensburg, Frankfurt am Main, Essen, Minden
2025-06-17
Recruiting
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
NCT06916507Parkinson's Disease
AbbVie
Observational
125
Allensbach, Heidelberg, Tübingen, Ulm, Wolfach, Erlangen, Ingolstadt, Munich
2025-05-06
Active, closed
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT06291220Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsABBV-453·Obinutuzumab
AbbVie
Phase 1
4
Ulm, Halle, Kiel, Berlin, Hamburg
2025-01-27
Recruiting
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
NCT06712628Moderate to Severe Rheumatoid Arthritis
AbbVie
Observational
678
Freiburg im Breisgau, Heidelberg, Tübingen, Ulm, Amberg, Augsburg, Marktredwitz, Munich
2024-11-07
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab
AbbVie
Phase 2
590
Freiburg im Breisgau, Mannheim, Ulm, Erlangen, Munich, Regensburg, Frankfurt am Main, Fulda
2024-09-04
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875Ulcerative Colitis
DrugsLutikizumab·Humira·Adalimumab
AbbVie
Phase 2
156
Ulm, Munich, Ludwigshafen am Rhein, Leipzig, Kiel, Hamburg
2024-03-23
Active, closed
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
NCT06107413Unresectable Metastatic Colorectal Cancer
DrugsFolinic acid·Telisotuzumab Adizutecan·Fluorouracil·Irinotecan
AbbVie
Phase 2
280
Mannheim, Tübingen, Ulm, Dresden, Berlin, Hamburg
2023-11-12
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
NCT05753501Hematologic Cancer
DrugVenetoclax
AbbVie
Phase 1
135
Ulm, Würzburg, Rostock, Homburg, Berlin, Hamburg
2023-06-09
Recruiting
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT04895436Chronic Lymphocytic Leukemia (CLL)
DrugsVenclexta·Obinutuzumab·Venetoclax
AbbVie
Phase 2
75
Mutlangen, Ulm, Landshut, Munich, Rostock, Cologne, Homburg, Dresden
2022-03-28
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Freiburg im Breisgau, Ulm, Bonn, Münster, Ludwigshafen am Rhein, Hamburg, Püttlingen
2022-01-13
Active, closed
A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting
NCT05094128Axial Spondylarthritis (r-axSpA)
DrugUpadacitinib
AbbVie
Observational
338
Baden-Baden, Heidelberg, Stuttgart, Tübingen, Ulm, Hoppegarten, Potsdam, Bruchhausen-Vilsen
2021-11-22
Active, closed
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
NCT04524611Crohn's Disease (CD)
DrugsSkyrizi·Risankizumab·Ustekinumab
AbbVie
Phase 3
527
Freiburg im Breisgau, Mannheim, Ulm, Erlangen, Regensburg, Frankfurt am Main, Hanover, Lüneburg
2020-09-30
Active, closed
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
NCT04086264Acute Myeloid Leukemia
DrugsIMGN632·Venclyxto·Decitabine·Venclexta
AbbVie
Phase 1/2
218
Ulm, Münster, Leipzig
2019-11-06
Active, closed
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135Ulcerative Colitis (UC)
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
1,242
Freiburg im Breisgau, Heidelberg, Mannheim, Ulm, Erlangen, Munich, Frankfurt am Main, Kassel
2018-08-28
Active, closed
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102Crohn's Disease
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
1,336
Freiburg im Breisgau, Heidelberg, Mannheim, Ulm, Dachau, Erlangen, Regensburg, Frankfurt am Main
2018-04-09
Active, closed
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
NCT03345823Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
747
Mannheim, Ulm, Erlangen, Frankfurt am Main, Saarbrücken, Kiel, Berlin, Essen
2018-03-21
Active, closed
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
NCT02993523Acute Myeloid Leukemia (AML)
DrugsAzacitidine·Venetoclax
AbbVie
Phase 3
443
Ulm, Frankfurt am Main, Münster, Halle, Hamburg, Hanover
2017-02-02
Active, closed
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
NCT02130362Crohn's Disease
AbbVie
Observational
1,446
Ulm, Erlangen, Munster, Osnabrück, Aachen, Dresden, Forchheim, Freiburg im Breisgau
2014-08-28
Active, closed
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
NCT01848561Ulcerative Colitis (UC)
AbbVie
Observational
8,250
Freiburg im Breisgau, Heidelberg, Mannheim, Sigmaringen, Ulm, Erlangen, Memmingen, Munich
2013-04-29
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 1 October 2026. https://priyalifescience.com/clinical-trials-germany/city/ulm

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies with a site in Ulm that also match the filters currently applied.

How many clinical trials are recruiting in Ulm?

5 of the 21 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 1 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ulm), 21 studies
PhaseStudiesRecruitingShare
Phase 39142.9%
Observational5223.8%
Phase 24219%
Phase 1209.5%
Phase 1/2104.8%

Most active sponsors

Lead sponsors with the most studies (Ulm)
Lead sponsorStudiesRecruiting
AbbVie215
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.